Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
IRVINE , Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced the commencement of patient dosing in Mercury 3, the Company’s European Phase 3 clinical trial of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel onc